RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024 Big Pharma still needs to buy in order to find innovative treatments and replenish top lines.... "and the only way for them to solve this is through BD [business development] and M&A,” Chris Roop, head of Americas M&A at Jefferies Financial Group Inc. said. “I feel optimistic that we’ll continue to see deal-flow.”
J&J is one drugmaker that’s likely poised to participate in any rebound, according to Nauman Shah, global head of business development for its pharmaceutical segment.
“We certainly still have the financial capability and the power to be able to do deals regardless of what size they are,” he said in an interview at last week’s BIO International Convention in San Diego. “We’re going to focus more on deals that are in that five to let’s even call it $20 billion range if they make sense. We’re not afraid to go to those levels.”